584 Phase I/II study to evaluate the safety and tolerability of avelumab in combination with other anti-cancer therapies in patients with advanced malignancies

584 Phase I/II study to evaluate the safety and tolerability of avelumab in combination with other anti-cancer therapies in patients with advanced malignancies

Bibliographic Details
Main Authors:	Aung Naing, Funda Meric-Bernstam, Shubham Pant, Milind Javle, Juhee Song, Anas Alshawa, Bettzy Stephen, Abdulrazzak Zarifa, Jordi Rodon, Yali Yang, Robert A Wolff, Anne Knisely, Van Morris, Jibran Ahmed
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2023-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy
by: Linghua Wang, et al.
Published: (2023-08-01)

Implementation of a Novel Web-Based Lesion Selection Tool to Improve Acquisition of Tumor Biopsy Specimens
by: Mingxuan Xu, et al.
Published: (2021-05-01)

Selinexor (KPT-330) in Combination with Immune Checkpoint Inhibition in Uveal Melanoma: A Phase 1B Trial
by: Mohamed A. Gouda, et al.
Published: (2025-01-01)

Phase I study of sapanisertib (CB‐228/TAK‐228/MLN0128) in combination with ziv‐aflibercept in patients with advanced solid tumors
by: Niamh Coleman, et al.
Published: (2024-02-01)

Phase Ib/II Study of Lacnotuzumab in Combination with Spartalizumab in Patients with Advanced Malignancies
by: Jibran Ahmed, et al.
Published: (2024-05-01)

SENTINEL LYMPH NODE DISSECTION CONTROVERSIES
by: Funda Meriç Bernstam
Published: (2005-01-01)

BREAST CONSERVING SURGERY IN LOCALLY ADVANCED BREAST CANCER
by: Funda Meriç Bernstam
Published: (2006-01-01)

BREAST-CONSERVING THERAPY
by: Funda Meriç Bernstam
Published: (2005-01-01)

A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic Melanoma
by: Mohamed A. Gouda, et al.
Published: (2024-11-01)

Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition
by: Niamh Coleman, et al.
Published: (2021-12-01)

Oral manifestation associated with avelumab
by: Kevin Chung, et al.
Published: (2024-03-01)

Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations
by: Sarina A. Piha-Paul, et al.
Published: (2024-07-01)

Whole Genome Sequencing in Cancer Clinics
by: Ken Chen, et al.
Published: (2015-01-01)

Strategies for improving the management of immune-related adverse events
by: James L Gulley, et al.
Published: (2020-10-01)

Haplotype Analysis of the T-Cell Receptor Beta (TCRB) Locus by Long-amplicon TCRB Repertoire Sequencing
by: Timothy J Looney, et al.
Published: (2019-09-01)

EAV584 - ENVIRONMENTAL IMPACT ASSESSMENT. OCTOBER 2003
by: PPKAW, Pusat Pengajian Kejuruteraan Awam
Published: (2003)

EAP584 - ENVIRONMENTAL IMPACT ASSESSMENT. NOVEMBER 2005
by: PPKAW, Pusat Pengajian Kejuruteraan Awam
Published: (2005)

Avelumab for the treatment of patients with Merkel cell carcinoma
by: K. V. Orlova, et al.
Published: (2020-07-01)

Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences
by: Shuyang Yao, et al.
Published: (2022-05-01)

BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study
by: Blessie Elizabeth Nelson, et al.
Published: (2023-02-01)

EAP 584-4 ENVIRONMENTAL IMPACT ASSESSMENT OCT 04.
by: PPKAW, Pusat Pengajian Kejuruteraan Awam
Published: (2004)

EAP 584-4 - ENVIRONMENTAL IMPACT ASSESSMENT OKTOBER 04.
by: PPKAW, Pusat Pengajian Kejuruteraan Awam
Published: (2004)

EAP 584-4 - ENVIRONMENTAL IMPACT ASSESSMENT JANUARI 2013
by: PPKW, Pusat Pengajian Kejuruteraan Awam
Published: (2013)

EAP 584/4 - ENVIRONMENTAL IMPACT ASSESSMENT NOV 09.
by: PPKAW, Pusat Pengajian Kejuruteraan Awam
Published: (2009)

EAV584 - PENILAIAN KESAN ALAM SEKITAR. SEPTEMBER 2002
by: PPKAW, Pusat Pengajian Kejuruteraan Awam
Published: (2002)

EAP584-4 - ENVIRONMENTAL IMPACK ASSESSMENT NOVEMBER 2008
by: PPKAW, Pusat Pengajian Kejuruteraan Awam
Published: (2008)

EAP 584-4 - ENVIRONMENTAL IMPACT ASSESSMENT NOV 2008.
by: PPKAW, Pusat Pengajian Kejuruteraan Awam
Published: (2008)

EAP584 – Environmental Impact Assessment Duration : 2 hours
by: Awam, Pusat Pengajian Kejuruteraan
Published: (2022)

Characterization of compound 584, an Abl kinase inhibitor with lasting effects
by: Miriam Puttini, et al.
Published: (2008-05-01)

584 THE ETHICS OF CONSENT: UNDERSTANDING THE RISKS OF VAGINAL PROLAPSE SURGERY
by: V Tailor, et al.
Published: (2022-06-01)

Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory
by: Vivek Subbiah, et al.
Published: (2020-10-01)

Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial
by: Tito R. Mendoza, et al.
Published: (2022-08-01)

EAV 584-4 ENVIRONMENTAL IMPACT ASSESSMENT FEB-MAR 03.
by: PPKAW, Pusat Pengajian Kejuruteraan Awam
Published: (2003)

EAP 584-4 ENVIRONMENTAL IMPACT ASSESSMENT OCT- NOV 06.
by: PPKAW, Pusat Pengajian Kejuruteraan Awam
Published: (2006)

EAP 584-4 ENVIRONMENTAL IMPACT ASSESSMENT OCT-NOV 07.
by: PPKAW, Pusat Pengajian Kejuruteraan Awam
Published: (2007)

EAP 584/4 - ENVIRONMENTAL IMPACT ASSESSMENT (EIA) NOV 2010.
by: PPKAW, Pusat Pengajian Kejuruteraan Awam
Published: (2010)

EAP584 - (BM&BI) ENVIRONMENTAL IMPACT ASSESSMENT. OCTOBER 2004
by: PPKAW, Pusat Pengajian Kejuruteraan Awam
Published: (2004)

Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies
by: Omar Alhalabi, et al.
Published: (2023-04-01)

RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study
by: Blessie Elizabeth Nelson, et al.
Published: (2024-03-01)

Product review: avelumab, an anti-PD-L1 antibody
by: Julie M. Collins, et al.
Published: (2019-04-01)